On the morning of October 9, Yin Li, Secretary of the CPC Beijing Municipal Committee, met with Severin Schwan, Chairman of the Board of Roche Group, a leading Swiss medical corporation.
Yin Li noted that with rising living standard and aging population, the global demand for pharmaceuticals and healthcare continues to grow. Beijing’s major health indicators are among the best in the world, supported by rich pharmaceutical innovation resources, convenient policy services, and a thriving pharmaceutical and health industry. Currently, cutting-edge technologies such as artificial intelligence (AI) are advancing rapidly, highlighting the prominent trend of “AI plus healthcare”. Beijing is steadily improving its innovation ecosystem and accelerating forward-looking development of industries including intelligent diagnostics, surgical robots, and mobile healthcare. Roche Group is a world-leading biopharmaceutical and diagnostics enterprise. Beijing stands ready to work with Roche to seize opportunities, deepen mutually beneficial cooperation, and achieve win-win development. Yin hoped that Roche Group will expand its investment and business presence in Beijing. He encouraged the company to deepen its industry-university-research collaboration with Beijing’s local hospitals, research institutes, and pharmaceutical enterprises, and introduce more innovative drugs and advanced therapies in areas such as oncology, immunology, and neurodegenerative diseases. Yin also hoped that Roche will strengthen cross-sector cooperation with Beijing’s technology firms, and develop exemplary applications in AI-assisted drug development, intelligent detection and diagnosis, and digital health management, so as to jointly promote the development of digital healthcare. Beijing will continue to enhance facilitation measures in areas such as market access and intellectual property rights protection, aiming to foster a more favorable development environment for all enterprises in the capital.
Schwan noted that China boasts a vast pharmaceutical and health market, and Roche Group is committed to continuously reinforcing its presence in China to achieve further growth. Recognizing Beijing’s prominent advantages in the sector, Schwan stated that Roche Group will expand its investment and business presence in the capital. The Group intends to enhance collaborative innovation with Beijing’s research and medical institutions, promote the development of digital healthcare, and bring more high-quality drugs and diagnostic products to the market, thereby helping to improve people’s health and well-being.
Municipal leaders Xia Linmao, Jin Wei, and Zhao Lei attended the meeting.
